



# Addex Pharmaceuticals

ADX10061 Smoking Cessation Data  
1 October 2007



## Disclaimer

These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities.

These materials contain forward-looking statements based on the currently held beliefs and assumptions of the management of Addex Pharmaceuticals Ltd, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Addex Pharmaceuticals Ltd, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. Addex Pharmaceuticals Ltd disclaims any obligation to update these forward-looking statements to reflect future events or developments.

These materials are strictly confidential and must not be disclosed or distributed to third parties.

# ADX10061 Overview




- ADX10061 is a potent selective dopamine D1 receptor antagonist discovered and developed by Novo Nordisk for schizophrenia
  - It had activity in schizophrenia but not better than marketed D2 receptor antagonists
- CeNeS (later performed studies in sleep, showing that it improved sleep architecture)
- D1 implicated in cue induced craving (craving leads to relapse)
- D1 antagonism decreases nicotine self administration in animals
- ADX10061 in-licensed from CeNeS in 2002

# Phase IIa trial



- Double-blind, placebo-controlled trial
- PI's at U.S. sites performed bupropion & varenicline trials
- 145 smokers included in the intent to treat population
- Primary endpoint: Continuous abstinence during treatment weeks 4-7 (endpoint taken from bupropion & varenicline registrational studies)
- No separation of ADX10061 treated patients from placebo treated patients on the primary endpoint.
- Major secondary endpoints did not reach significance

# Pipeline



\* *inlicensed; not an allosteric modulator*

<sup>a</sup>NAM = negative allosteric modulator; <sup>b</sup>PAM = positive allosteric modulator

# Next Clinical Milestones



Timing	Event
Around end 4Q07	ADX10059 Phase IIa anxiety data
Mid-08	ADX10059 start Phase IIb GERD program
Mid-08	ADX10059 start Phase IIb migraine prevention program
2008	ADX48621 final Phase I data
2008	ADX63365 Phase I program starts
2008/2009	ADX71441 Phase I program starts



***allosteric modulators for human health***

[www.addexpharma.com](http://www.addexpharma.com)